Skip to main content
SpringerLink
Log in

Interferon Free Hepatitis C Treatment Regimens: The Beginning of Another Era

  • Liver (BR Bacon, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Hepatitis C is a virus affecting millions worldwide and is a major health risk. With the potentially severe adverse event profile of the current backbone of therapy, interferon, there is an impetus to discover interferon free treatment regimens. With the development of new oral direct acting antivirals, interferon free regimens may be available in the next few years. This article discusses some of the preliminary data from interferon free studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;21(244):359–62.

    Article  Google Scholar 

  2. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426–332.

    Article  PubMed  CAS  Google Scholar 

  3. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–92.

    Article  Google Scholar 

  4. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352(9138):1426–32.

    Article  PubMed  CAS  Google Scholar 

  5. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther. 2000;68(5):556–67.

    Article  PubMed  CAS  Google Scholar 

  6. Grace M, Youngster S, Gitlin G, et al. Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res. 2001;21(12):1103–15.

    Article  PubMed  CAS  Google Scholar 

  7. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon a-2a for the treatment of hepatitis C. Bioconjug Chem. 2001;12(2):195–202.

    Article  PubMed  CAS  Google Scholar 

  8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–65.

    Article  PubMed  CAS  Google Scholar 

  9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–82.

    Article  PubMed  CAS  Google Scholar 

  10. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Eng J Med. 2009;361:580–93.

    Article  CAS  Google Scholar 

  11. Flamm S, Lawitz E, Jacobson I, et al. High Sustained Virologic Response (SVR) among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir (BOC) plus peginterferon alfa-2A/ribavirin. J Hepatol. 2011;54:A1366.

    Article  Google Scholar 

  12. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–17.

    Article  PubMed  CAS  Google Scholar 

  13. Poordad F, Chee GM: Pharmacology and mechanisms of action of antiviral drugs: Ribavirin analogues. Advanced Therapy for Hepatitis C Infection. 2011, Wiley-Blackwell (In press)

  14. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.

    Article  PubMed  CAS  Google Scholar 

  15. Poordad F, McCone Jr J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206.

    Article  PubMed  CAS  Google Scholar 

  16. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.

    Article  PubMed  CAS  Google Scholar 

  17. Gale M, Katze MG. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon induced protein kinase. Pharmacol Ther. 1998;78:29–46.

    Article  PubMed  CAS  Google Scholar 

  18. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.

    Article  PubMed  CAS  Google Scholar 

  19. • Thompson AJ, Muir AJ, Sulkowski MS, et al.: IL28B Polymorphism Improves Viral Kinetics and Is the Strongest Pre-treatment Predictor of SVR in HCV-1 Patients. Gastroenterology. 2010; 139:120–129. A key paper describing the clinical effects of the IL28B polymorphism on response rates in HCV genotype 1 patients.

    Article  PubMed  CAS  Google Scholar 

  20. Poordad F, Bronowicki J-P, Gordon SC, et al.: IL28B Polymorphism Predicts Virologic Response in Patients With Hepatitis C Genotype 1 Treated With Boceprevir (Boc) Combination Therapy. Gastroenterology 2011;A1864

  21. Zeuzem S, Andreone P, Pol S, et al. REALIZE study team: telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417–28.

    Article  PubMed  CAS  Google Scholar 

  22. • Gane EJ, Roberts SK, Stedman CA, et al.: Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376:1467–75. The first study assessing two compounds with different mechanisms of action targeting HCV and showing good antiviral effects. This ultimately allowed for the discussion of interferon free regimens.

    Article  PubMed  CAS  Google Scholar 

  23. • Lok A, Gardiner D, Lawitz E, et al.: Quadruple therapy with MBS-790052, BMS-650032 and peginterferon/ribavirin for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. J Hepatol 2011; 54(suppl):S536. An important study, and the first to show that null patients can be cured of HCV using only 2 oral agents for 24 weeks. This presentation changed many perspectives about the possibilities of what interferon free regimens can do.

    Article  Google Scholar 

  24. Lalezari J, Lawitz E, Rodriguez-Torres M, et al. PSI-7977 QD with Peg/RBV: 12-week Safety, RVR, cEVR, and SVR12 in treatment-naïve patients with HCV GT2 or GT3. J of Hepatology. 2011;54:A61.

    Google Scholar 

  25. Lawitz E, Rodriguez-Torres M, Denning J, et al. Once daily dual-nucleotide combination of PSI-928 and PSI-7977 provides 95% HCV RNA<LOD at Day 14: first purine/prymimidine clinical combination data (The Nuclear Study). J Hepatol. 2011;54:A1370.

    Google Scholar 

Download references

Disclosure

F. Poordad has received consultant fees and grant funding from Merck, Vertex, Gilead, Pharmassett, Anadys, Achillion, BMS, Abbott and Genentech, and has received payment for development of educational presentations from Vertex, Merck, Genentech, and Gilead; G. Chee reported no potential conflicts of interest relevant to this article.

Author information

Authors and Affiliations

  1. Hepatology and Liver Transplantation, Cedars-Sinai Medical Center, 8635 W 3rd St, Suite 1060, Los Angeles, CA, 90048, USA

    Fred Poordad

  2. Hepatology Department, Cedars-Sinai Medical Center, 8631 W 3rd St, Suite 430, Los Angeles, CA, 90048, USA

    Grace M. Chee

Authors
  1. Fred Poordad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Grace M. Chee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fred Poordad.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Poordad, F., Chee, G.M. Interferon Free Hepatitis C Treatment Regimens: The Beginning of Another Era. Curr Gastroenterol Rep 14, 74–77 (2012). https://doi.org/10.1007/s11894-011-0229-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-011-0229-1

Keywords

Search

Navigation